



## ASX Announcement

24<sup>th</sup> July 2020

# Conference Call Recording

---

**Invex Therapeutics Ltd** (ASX: **IXC**, **Invex** or the **Company**) has provided the audio recording of the investor conference call held on 23<sup>rd</sup> July 2020 following receipt of preliminary regulatory feedback from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), regarding its proposed development plans for Presendin<sup>™</sup> in idiopathic intracranial hypertension (IIH) on its website.

The recording can be accessed at the following link:

<https://invextherapeutics.com/wp-content/uploads/2020/07/Invex-Therapeutics-Regulatory-Update-10008874-230720.mp3>

***This release dated 24<sup>th</sup> July has been authorised for lodgement to the ASX by Narelle Warren, CFO and Company Secretary***

**ENDS**

---

## For more information, please contact:

### Investors

Dr Thomas Duthy  
Nemean Group  
[tduthy@nemean.com.au](mailto:tduthy@nemean.com.au)  
+61 402 493 727

### Media

Margie Livingston  
Ignite Communications  
[margie@ignitecommunications.com.au](mailto:margie@ignitecommunications.com.au)  
+61 438 661 131

## About Invex Therapeutics Ltd

---

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin<sup>™</sup>.  
[www.invextherapeutics.com](http://www.invextherapeutics.com).